Valuation: BioNTech SE

Market Cap 23.85B 144B 27.84B 22.32B 20.43B 38.34B 2,664B 38.84B 264B 103B 1,338B 105B 102B 4,426B P/E 2026 *
-17.2x
P/E 2027 * -18.3x
Enterprise Value 12.48B 75.19B 14.57B 11.68B 10.69B 20.06B 1,394B 20.33B 138B 53.81B 700B 54.71B 53.52B 2,316B EV / Sales 2026 *
6.91x
EV / Sales 2027 * 7.5x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day+31.60%
1 week+19.93%
Current month+25.71%
1 month+23.23%
3 months+27.12%
6 months+1.66%
Current year+10.39%
1 week 29.81
Extreme 29.81
38.8
1 month 26.28
Extreme 26.28
38.8
Current year 25.78
Extreme 25.78
41
1 year 25.78
Extreme 25.78
41
3 years 25.78
Extreme 25.78
49.05
5 years 25.78
Extreme 25.78
66.08
10 years 25.78
Extreme 25.78
66.08
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 2017-12-31
Chief Executive Officer 60 2008-06-01
Director of Finance/CFO - 2025-06-30
Director TitleAgeSince
Chairman 55 2008-06-01
Director/Board Member 69 2008-06-01
Director/Board Member 65 2017-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+31.60%+19.93% - - 27.86B
-3.00%+0.33%+77.39%+109.41% 73.96B
+1.90%+19.57%+60.16%+101.03% 64.66B
+0.55%+1.64%-5.15%+471.68% 27.32B
+5.12%+25.22%+5.24%-0.82% 27.86B
+2.74%+11.55%+66.56%+27.34% 25.97B
+0.47%+6.22%+39.36%-12.38% 19.98B
+1.82%-3.11%+245.72%+423.83% 17.84B
+0.94%+2.38%+24.83%+552.12% 16.24B
+0.73%+5.54%+39.71%+153.07% 13.3B
Average +4.20%+6.16%+61.53%+202.81% 31.9B
Weighted average by Cap. +3.34%+6.66%+60.77%+162.00%

Financials

2026 *2027 *
Net sales 1.81B 10.89B 2.11B 1.69B 1.55B 2.9B 202B 2.94B 19.98B 7.79B 101B 7.92B 7.75B 335B 1.84B 11.11B 2.15B 1.72B 1.58B 2.96B 206B 3B 20.38B 7.95B 103B 8.08B 7.91B 342B
Net income -1.35B -8.12B -1.57B -1.26B -1.15B -2.17B -151B -2.2B -14.91B -5.81B -75.66B -5.91B -5.78B -250B -1.31B -7.91B -1.53B -1.23B -1.12B -2.11B -147B -2.14B -14.52B -5.66B -73.68B -5.76B -5.63B -244B
Net Debt -11.37B -68.48B -13.27B -10.64B -9.74B -18.27B -1,270B -18.52B -126B -49.01B -638B -49.83B -48.75B -2,110B -10.03B -60.43B -11.71B -9.39B -8.59B -16.12B -1,120B -16.34B -111B -43.24B -563B -43.97B -43.01B -1,862B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
26-08-21 R$36.23 +31.60% 6,818
26-08-20 R$36.04 +1.32% 1,459
26-08-19 R$35.57 +17.63% 21,028
26-08-18 R$30.24 +1.31% 170
26-08-17 R$29.85 -1.19% 10
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
94.94EUR
Average target price
104.04EUR
Spread / Average Target
+9.58%

Quarterly revenue - Rate of surprise